When it comes to developmental drugs, there's a lot of rumors and speculation thrown around about a drug's ultimate success or failure in clinical trials. When the time comes for that hard data, share prices are bound to soar or plummet in a big way. That's what happened today with BioMarin (NASDAQ:BMRN), which published phase 3 data around its drug treating an ultra-rare disorder called Morquio A syndrome. Follow along in the video as Brenton Flynn and Max Macaluso discuss today's news and a couple more companies in a similar situation to BioMarin.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 12/03/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return